ReviewMolecules (Basel, Switzerland)2022
Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 188 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
188 citing papers in PubMed.
- Discovery of novel coumarin-containing triazolo[1,5-a]pyrimidine derivatives as potent ABCB1 inhibitor for modulation of multidrug resistance.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Article
- Extracellular vesicles in osteosarcoma: bridging resistance, immunity, and clinical translation.Journal of bone oncology · 2026Review
- Two Novel 1,4-Naphthoquinone Derivatives as Potent Agents Against Multidrug-Resistant Staphylococcus aureus and Pathogenic Gram-Positive Bacteria.Drug development research · 2026Article
- TrxR Inhibition and Nrf2-FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance.Drug development research · 2026Review
- Evaluation of the Antioxidant, Anti-Inflammatory, and Antimicrobial Activity of aInternational journal of molecular sciences · 2026Article
- XMU-MP-1, the Hippo Signaling Pathway MST-1 Kinase Inhibitor, Prevents the Development of Drug Resistance to Doxorubicin in Hematological Tumor Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Epidemiological trends of multidrug-resistant organisms in a tertiary-care pediatric hospital, 2017-2023.Italian journal of pediatrics · 2026Article
- Review
- Review
- Detection and Characterization of ESBL-Producing and Carbapenem-Resistant Klebsiella pneumoniae in Ornamental Birds and Their Surrounding Environments.MicrobiologyOpen · 2026Article
- Engineered extracellular vesicles for combinatorial cancer therapy and imaging.Acta pharmaceutica Sinica. B · 2026Review
- A Review of the Properties of Clinically Evaluated Plant-Derived Agents in the Treatment of Respiratory Infections.Nutrients · 2026Review
- Wogonin Ameliorates the Oxidative Stress, Apoptosis, and Extracellular Matrix Degradation of Nucleus Pulposus Cells Mediated byInternational journal of molecular sciences · 2026Article
- A Comprehensive Review on the Anticancer Activity of Plant Peptides and Their Mechanisms of Action.Foods (Basel, Switzerland) · 2026Review
- Draft genome sequences of 16 multidrug-resistantMicrobiology resource announcements · 2026Article
- Characterization of the YCjN ABC Transporter in Escherichia coli: Role in Maltose and Ethidium Bromide Transport.Molecular biotechnology · 2026Article
- Reining in Multidrug Resistance Protein 1 via Binding Its Flexible Interdomain Linker with Sequence-Selective Peptide-Binding Nanoparticles.Biomacromolecules · 2026Article
- Multimatrix surveillance of multidrug-resistant and ESBL-producingVeterinary world · 2026Article
- Draft genome sequence of a multidrug-resistantMicrobiology resource announcements · 2026Article
128 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance is a leading concern in public health. It describes a complex phenotype whose predominant feature is resistance to a wide range of structurally unrelated cytotoxic compounds, many of which are anticancer agents. Multidrug resistance may be also related to antimicrobial drugs, and is known to be one of the most serious global public health threats of this century. Indeed, this phenomenon has increased both mortality and morbidity as a consequence of treatment failures and its incidence in healthcare costs. The large amounts of antibiotics used in human therapies, as well as for farm animals and even for fishes in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. It is not negligible that the ongoing COVID-19 pandemic may further contribute to antimicrobial resistance. In this paper, multidrug resistance and antimicrobial resistance are underlined, focusing on the therapeutic options to overcome these obstacles in drug treatments. Lastly, some recent studies on nanodrug delivery systems have been reviewed since they may represent a significant approach for overcoming resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.